ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.067,91
-0,31%
S&P 500
5.487,03
0,25%
Dow Jones
38.834,86
0,15%
Euro vs US Dollar
1,07432
0,03%
Bitcoin
64.821,50
-0,49%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Talaris Therapeutics Inc (TALS)

  7. Talaris Therapeutics Inc (TALS) News

TALS

Talaris Therapeutics (TALS)

Talaris Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:TALS
DatumZeitQuelleÜberschriftSymbolFirma
19/04/202422h05Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:TALSTalaris Therapeutics Inc
19/04/202422h04Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:TALSTalaris Therapeutics Inc
19/04/202422h02Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:TALSTalaris Therapeutics Inc
19/03/202422h10Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TALSTalaris Therapeutics Inc
19/03/202422h02Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:TALSTalaris Therapeutics Inc
19/03/202412h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TALSTalaris Therapeutics Inc
21/11/202300h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TALSTalaris Therapeutics Inc
21/11/202300h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TALSTalaris Therapeutics Inc
06/11/202322h30Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TALSTalaris Therapeutics Inc
30/10/202321h15Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:TALSTalaris Therapeutics Inc
27/10/202323h17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TALSTalaris Therapeutics Inc
27/10/202322h02Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TALSTalaris Therapeutics Inc
26/10/202323h34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TALSTalaris Therapeutics Inc
26/10/202323h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TALSTalaris Therapeutics Inc
26/10/202322h46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TALSTalaris Therapeutics Inc
21/10/202303h23Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TALSTalaris Therapeutics Inc
17/10/202323h47GlobeNewswire Inc.Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline BioNASDAQ:TALSTalaris Therapeutics Inc
10/10/202322h32Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:TALSTalaris Therapeutics Inc
10/10/202322h30Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:TALSTalaris Therapeutics Inc
07/10/202302h01Dow Jones NewsStocks to Watch: Shift Technologies, Talaris Therapeutics, Lockheed MartinNASDAQ:TALSTalaris Therapeutics Inc
06/10/202323h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TALSTalaris Therapeutics Inc
06/10/202323h27Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:TALSTalaris Therapeutics Inc
06/10/202323h26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TALSTalaris Therapeutics Inc
06/10/202323h09GlobeNewswire Inc.Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline BioNASDAQ:TALSTalaris Therapeutics Inc
04/10/202314h30GlobeNewswire Inc.New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris TherapeuticsNASDAQ:TALSTalaris Therapeutics Inc
26/09/202314h24Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:TALSTalaris Therapeutics Inc
26/09/202314h21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TALSTalaris Therapeutics Inc
15/09/202312h31Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TALSTalaris Therapeutics Inc
15/09/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:TALSTalaris Therapeutics Inc
13/09/202322h28Edgar (US Regulatory)Form S-4/A - Registration of securities, business combinations: [Amend]NASDAQ:TALSTalaris Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:TALS

Kürzlich von Ihnen besucht

NASDAQ
MITAW
Coliseum Acquisition
BIT
UC467N
Unicredit Bank
USOTC
SDNSF
Sumitomo Densetsu (PK)
LSE
DAR
Dar Global
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten